|Advaxis, Inc. (NASDAQ:ADXS) Jumps 4% On Clinical Trial Collaboration Agreement|
|By Josh Gee|
|Monday, 06 April 2015 15:49|
Clinical-stage biotechnology company, Advaxis, Inc.(NASDAQ:ADXS), which is developed cancer immunotherapies has stated that it would be entering into clinical trial collaboration agreement with Radiation Therapy Oncology Group (RTOG) Foundation for evaluating efficacy and safety of ADXS-HPV (ADXS11-001), in a pivotal Phase 2/3 anal cancer trial, that would be run by NRG Oncology.
The ADXS-HPV is an investigational Lm-LLO immunotherapy which aims to generate immunity to HPV-associated tumor specific oncogene.
RTOG Foundation along with NRG Oncology would be conducting an adequate and well-controlled Phase 2/3 clinical trial of concurrent chemotherapy of mitomycin C/5FU as well as radiation therapy (CCRT) vis-a-vis CCRT combined with ADXS-HPV in the treatment of high-risk locally advanced anal cancer.
RTOG Foundation Chairman of the Board and NRG Oncology Group Chair, Walter J. Curran, Jr., MD, has stated that ADXS-HPV’s ability to ensure potential treatment of multiple cancers includes cervical cancer and anal cancer and that the firm is looking forward in initiating this study in anal cancer.
On the other hand, Executive Vice President and Chief Medical Officer of Advaxis, David J. Mauro, MD, PhD, opined that the firm is excited to enter into the agreement with NRG Oncology and is looking forward to build on the initial results observed in ongoing Phase 1/2 study of ADXS-HPV in anal cancer being conducted by Professor Howard Safran MD of Brown University Oncology Group.
The Radiation Therapy Oncology Group (RTOG) is now an international leader in conducting Phase 2 and 3 multi-institutional clinical trials focussing on radiation oncology issues.
The firm has made new standards over the last four decades for improving the quality and survival life of cancer patients as well as and developed new processes for the study and application of innovative radiotherapy technologies.
RTOG Foundation is a Philadelphia based organization which is continuing National Cancer Institute funded research activities through NRG Oncology as one of its three founding members.
Shares of ADXS jumped 4% to $16.32 in mid day session.